Sign in

    Keros Therapeutics (KROS)

    Q4 2024 Earnings Summary

    Reported on Jan 1, 1970 (Before Market Open)
    Pre-Earnings Price$10.91Last close (Feb 25, 2025)
    Post-Earnings Price$10.94Open (Feb 26, 2025)
    Price Change
    $0.03(+0.27%)
    MetricYoY ChangeReason

    Total Revenue

    +2086% (from $0.14M in Q4 2023 to $3.03M in Q4 2024)

    Total Revenue surged dramatically as the company transitioned from minimal revenue of $0.14M in Q4 2023 to $3.03M in Q4 2024, indicating a major commercial ramp-up likely driven by new product sales or expanded contractual agreements.

    Service Revenue

    Not directly compared YoY; $0.43M in Q4 2024 reported

    Service Revenue contributed $0.43M in Q4 2024, indicating a key but smaller revenue stream that complements overall revenue growth, suggesting diversification in revenue sources compared to prior periods.

    Net Loss Attributable to Common Stockholders

    Increased by 14% (from $(40,243)K in Q4 2023 to $(46,026)K in Q4 2024)

    Net Loss expanded by roughly 14% which reflects increased operating expenses–possibly higher R&D and commercialization costs–to support the revenue ramp-up, thereby deepening the loss despite higher topline performance.

    Operating Activities Cash Outflow

    Increased from $(30,500)K in Q3 2024 to $(46,008)K in Q4 2024

    Operating cash outflows rose by over 50% between quarters, driven by higher operating expenses and likely increased investments in production and commercialization, underscoring elevated costs as operations scale up.

    Financing Activities Net Cash

    Provided $75,544K in Q4 2024, resulting in a net cash increase of $29,247K during the quarter

    Financing activities generated strong cash inflows—mainly through equity offerings or ATM sales—that boosted cash by $29,247K in Q4 2024, reflecting proactive capital raising to support the growth initiatives that drove the revenue expansion.

    Balance Sheet (Cash, Assets, Liabilities, Equity)

    Cash increased to $559,931K; Total Assets to $615,886K; Liabilities declined to $44,333K; Equity increased to $571,553K

    The improved balance sheet in Q4 2024 reflects the impact of robust financing, with cash reserves rising significantly and total assets growing, while disciplined management reduced total liabilities and enhanced stockholders’ equity compared to previous periods.

    Research analysts covering Keros Therapeutics.